Jonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $148.35, for a total value of $2,670,300.00. Following the completion of the sale, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at approximately $157,929,404.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $154.88 on Friday. The company has a market capitalization of $13,440.00, a P/E ratio of 50.35, a price-to-earnings-growth ratio of 2.26 and a beta of 0.46. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a one year low of $113.47 and a one year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 EPS. equities research analysts expect that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/11/18/jonathan-w-ayers-sells-18000-shares-of-idexx-laboratories-inc-idxx-stock-2.html.

A number of equities research analysts have commented on the company. BidaskClub cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research note on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Friday, July 28th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $173.67.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of IDEXX Laboratories by 4.0% during the second quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock valued at $1,495,488,000 after buying an additional 354,024 shares during the last quarter. BlackRock Inc. boosted its position in shares of IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after buying an additional 673,347 shares during the last quarter. Koch Industries Inc. boosted its position in shares of IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after buying an additional 1,396,113 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of IDEXX Laboratories by 38.6% during the second quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after buying an additional 376,300 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of IDEXX Laboratories by 42.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after buying an additional 392,790 shares during the last quarter. 88.03% of the stock is currently owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply